Overexpression of topoisomerase II alpha protein is a factor for poor prognosis in patients with luminal B breast cancer

BACKGROUND: The prognostic value and the best method of testing of topoisomerase II alpha (TOP2A) status have not been established in modern tailored therapy based on breast cancer subtype. RESULTS: The frequencies of TOP2A overexpression and TOP2A amplified were 55.8% and 9.5%, respectively. TOP2A...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncotarget
Prif Awduron: Shigematsu, Hideo, Ozaki, Shinji, Yasui, Daisuke, Yamamoto, Hideki, Zaitsu, Junichi, Taniyama, Daiki, Saitou, Akihisa, Kuraoka, Kazuya, Hirata, Taizo, Taniyama, Kiyomi
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Impact Journals LLC 2018
Pynciau:
Research Paper
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6003555/
https://ncbi.nlm.nih.gov/pubmed/29928479
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25468
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg